3.13
price down icon4.86%   -0.16
after-market Dopo l'orario di chiusura: 3.13
loading

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

pulisher
11:32 AM

Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com

11:32 AM
pulisher
09:15 AM

Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

09:15 AM
pulisher
07:14 AM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛

07:14 AM
pulisher
04:02 AM

Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest

04:02 AM
pulisher
Jul 24, 2025

Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com

Jul 24, 2025
pulisher
Jul 24, 2025

Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative

Jul 23, 2025
pulisher
Jul 23, 2025

Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView

Jul 23, 2025
pulisher
Jul 23, 2025

Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade

Jul 23, 2025
pulisher
Jul 23, 2025

Positive Week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Institutional Investors Who Lost 64% Over the Past Year - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com

Jul 23, 2025
pulisher
Jul 23, 2025

Where are the Opportunities in (IOVA) - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Iovance Biotherapeutics Inc. stock priceRapid profit acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics Shares Soar 14.46% on FDA Approval, Leadership Changes - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Jul 22, 2025
pulisher
Jul 21, 2025

Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com

Jul 21, 2025
pulisher
Jul 21, 2025

This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - The Motley Fool

Jul 21, 2025
pulisher
Jul 21, 2025

Teacher Retirement System of Texas Has $191,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Jul 21, 2025
pulisher
Jul 20, 2025

Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World

Jul 18, 2025
pulisher
Jul 17, 2025

Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade

Jul 17, 2025
pulisher
Jul 16, 2025

Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail

Jul 14, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):